{"id":66731,"date":"2026-05-29T21:12:30","date_gmt":"2026-05-29T13:12:30","guid":{"rendered":"https:\/\/flcube.com\/?p=66731"},"modified":"2026-05-29T21:12:31","modified_gmt":"2026-05-29T13:12:31","slug":"salvectors-receives-nmpa-clinical-approval-for-yb1-x7-worlds-first-oncolytic-salmonella-therapy-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66731","title":{"rendered":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#8217;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Salvectors<\/strong>, a China-based oncolytic bacteria therapy developer, announced it has received <strong>tacit clinical approval<\/strong> from the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for its <strong>YB1-X7<\/strong>, a <strong>next-generation oncolytic bacteria therapy<\/strong>. The investigational treatment will now advance into clinical assessment for <strong>advanced solid tumors<\/strong>, marking a significant milestone in bacterial cancer therapy development.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Tacit clinical approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td><strong>Dual-phase clinical development<\/strong> in both China and United States<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td><strong>World&#8217;s first oncolytic Salmonella therapy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-proprietary-technology-platform\" class=\"wp-block-heading\">Proprietary Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chassis Strain:<\/strong> Proprietary, de novo engineered Salmonella strain<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> &#8220;Hypoxia-driven proliferation and aerobic lysis&#8221; regulatory switch<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n\n\n\n<li><strong>Tumor Targeting:<\/strong> Highly selective colonization of hypoxic tumor microenvironments<\/li>\n\n\n\n<li><strong>Safety Feature:<\/strong> Rapid clearance in normal aerobic tissues<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Dual action of direct tumor lysis and potential immune activation<\/li>\n\n\n\n<li><strong>Preclinical Validation:<\/strong> Nonclinical studies demonstrated robust efficacy with favorable safety profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-manufacturing-amp-cmc-partnership\" class=\"wp-block-heading\">Manufacturing &amp; CMC Partnership<\/h2>\n\n\n\n<h3 id=\"h-porton-advanced-solution-ltd-critical-cmc-services-provider\" class=\"wp-block-heading\">Porton Advanced Solution Ltd. \u2013 Critical CMC Services Provider<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Service Category<\/th><th>Specific Activities<\/th><\/tr><\/thead><tbody><tr><td><strong>Cell Bank Development<\/strong><\/td><td>Master and working cell bank construction<\/td><\/tr><tr><td><strong>Process Development<\/strong><\/td><td>Scalable manufacturing process optimization<\/td><\/tr><tr><td><strong>GMP Manufacturing<\/strong><\/td><td>Good Manufacturing Practice production<\/td><\/tr><tr><td><strong>Quality Assurance<\/strong><\/td><td>Comprehensive quality studies and release testing<\/td><\/tr><tr><td><strong>Regulatory Support<\/strong><\/td><td>IND filing support for both China and U.S. jurisdictions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<h3 id=\"h-oncolytic-bacteria-therapeutic-landscape\" class=\"wp-block-heading\">Oncolytic Bacteria Therapeutic Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Emerging Modality:<\/strong> Bacterial therapies represent next frontier beyond viral oncolytics and cell therapies<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Advanced solid tumors remain challenging to treat with conventional approaches<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> YB1-X7&#8217;s hypoxia-specific targeting addresses key safety concerns that have limited previous bacterial therapies<\/li>\n\n\n\n<li><strong>Global First-Mover Advantage:<\/strong> World&#8217;s first oncolytic Salmonella positions Salvectors as category leader<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-context-in-oncolytic-therapies\" class=\"wp-block-heading\">Competitive Context in Oncolytic Therapies<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform Type<\/th><th>Leading Examples<\/th><th>Development Stage<\/th><th>Salvectors&#8217; YB1-X7 Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncolytic Viruses<\/strong><\/td><td>T-VEC (Amgen), Delytact (Daiichi Sankyo)<\/td><td>Approved\/Phase III<\/td><td>Bacterial platform may penetrate different tumor types<\/td><\/tr><tr><td><strong>Engineered Bacteria<\/strong><\/td><td>Various early-stage programs<\/td><td>Preclinical\/Phase I<\/td><td><strong>First Salmonella-based therapy in dual-country clinical development<\/strong><\/td><\/tr><tr><td><strong>Cell Therapies<\/strong><\/td><td>CAR-T, TIL therapies<\/td><td>Approved for hematologic\/some solid tumors<\/td><td>Potential for off-the-shelf administration vs. personalized<\/td><\/tr><tr><td><strong>Traditional Oncolytics<\/strong><\/td><td>Chemotherapy, targeted agents<\/td><td>Standard of care<\/td><td>Novel mechanism may overcome resistance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-strategy-amp-commercial-outlook\" class=\"wp-block-heading\">Development Strategy &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Jurisdiction Approach:<\/strong> Simultaneous clinical development in China and U.S. accelerates global timeline<\/li>\n\n\n\n<li><strong>Manufacturing Readiness:<\/strong> GMP capabilities established through Porton partnership<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> NMPA tacit approval provides foundation for potential accelerated development<\/li>\n\n\n\n<li><strong>Platform Potential:<\/strong> Success could validate entire oncolytic bacteria platform for multiple solid tumor indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for YB1-X7. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges unique to live bacterial products, and competitive dynamics in the emerging oncolytic therapy landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[62,4763],"class_list":["post-66731","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-clinical-trial-approval-initiation","tag-salvectors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#039;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#039;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T13:12:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T13:12:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#8217;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors\",\"datePublished\":\"2026-05-29T13:12:30+00:00\",\"dateModified\":\"2026-05-29T13:12:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731\"},\"wordCount\":479,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Salvectors\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66731#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66731\",\"name\":\"Salvectors Receives NMPA Clinical Approval for YB1-X7, World's First Oncolytic Salmonella Therapy for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T13:12:30+00:00\",\"dateModified\":\"2026-05-29T13:12:31+00:00\",\"description\":\"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66731\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#8217;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World's First Oncolytic Salmonella Therapy for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66731","og_locale":"en_US","og_type":"article","og_title":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World's First Oncolytic Salmonella Therapy for Advanced Solid Tumors","og_description":"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.","og_url":"https:\/\/flcube.com\/?p=66731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T13:12:30+00:00","article_modified_time":"2026-05-29T13:12:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#8217;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors","datePublished":"2026-05-29T13:12:30+00:00","dateModified":"2026-05-29T13:12:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66731"},"wordCount":479,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Salvectors"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66731#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66731","url":"https:\/\/flcube.com\/?p=66731","name":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World's First Oncolytic Salmonella Therapy for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T13:12:30+00:00","dateModified":"2026-05-29T13:12:31+00:00","description":"Salvectors, a China-based oncolytic bacteria therapy developer, announced it has received tacit clinical approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for its YB1-X7, a next-generation oncolytic bacteria therapy. The investigational treatment will now advance into clinical assessment for advanced solid tumors, marking a significant milestone in bacterial cancer therapy development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66731"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salvectors Receives NMPA Clinical Approval for YB1-X7, World&#8217;s First Oncolytic Salmonella Therapy for Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66731\/revisions"}],"predecessor-version":[{"id":66732,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66731\/revisions\/66732"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}